{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:10:27Z","timestamp":1776651027879,"version":"3.51.2"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Voriconazole is the first-line therapy for invasive aspergillosis (IA). To determine the minimum inhibitory concentration of Aspergillus, a voriconazole pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) model linked to galactomannan response was developed and evaluated, and its clinical correlation for IA treatment was elucidated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Adult patients with probable or definite IA and at least one serum voriconazole measurement were included. A two-compartment voriconazole PK model was linked to a previously described PD model of galactomannan response. PK and PD parameters were estimated using a nonparametric adaptive grid technique. The relationship between the ratio of voriconazole exposure that induced half-maximum galactomannan response (EC50) and the observed terminal galactomannan concentration was evaluated. The factors associated with the PK\u2013PD parameters and mortality were also determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Between January 2013 and December 2022, 41 patients were prescribed voriconazole for IA. The 30-day mortality rate was 17%. A high correlation was found for the observed\u2013predicted Bayesian posterior estimates of voriconazole and galactomannan levels. Moreover, a nonlinear relationship was identified between AUC:EC50 and terminal galactomannan. The factors associated with higher AUC:EC50 were intravenous administration and intubation. In the survival analysis, higher EC50 tended to be associated with mortality, higher AUC was significantly associated with increased mortality, and higher AUC:EC50 tended to be associated with higher mortality. After adjusting for the intravenous route, higher AUC and AUC:EC50 were not associated with mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Individual EC50 estimation can provide insights into in vivo host and organism responses. Elevated EC50 showed comparable and unfavorable trends to higher minimum inhibitory concentration. Thus, determining EC50 might help guide individualized target serum voriconazole levels.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001268","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T23:00:10Z","timestamp":1729638010000},"page":"378-384","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Mechanism-Based Pharmacokinetic\/Pharmacodynamic Model of Voriconazole for Predicting the Clinical Outcomes of Adult Patients With Invasive Aspergillosis"],"prefix":"10.1097","volume":"47","author":[{"given":"Monchai","family":"Duangpraphat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Ratchadhevi, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Centre for Antimicrobial Optimisation, Imperial College London, United Kingdom;"},{"name":"David Price Evans Global Health and Infectious Diseases Research Group, University of Liverpool, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"Rawson","sequence":"additional","affiliation":[{"name":"Centre for Antimicrobial Optimisation, Imperial College London, United Kingdom;"},{"name":"NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Hospital, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichai","family":"Santimaleeworagun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Ratchadhevi, Bangkok, Thailand;"},{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Silpakorn University, Nakorn Pathom, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Worapong","family":"Nasomsong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Ratchadhevi, Bangkok, Thailand;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison H.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Centre for Antimicrobial Optimisation, Imperial College London, United Kingdom;"},{"name":"David Price Evans Global Health and Infectious Diseases Research Group, University of Liverpool, United Kingdom;"},{"name":"NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Hospital, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1761-0978","authenticated-orcid":false,"given":"Vasin","family":"Vasikasin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Ratchadhevi, Bangkok, Thailand;"},{"name":"NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, Hammersmith Hospital, London, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis."},{"key":"R2-20250509","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol."},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/phar.1631","article-title":"Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections","volume":"35","author":"Wang","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-157","DOI":"10.12688\/f1000research.10216.1","article-title":"Challenges in microbiological diagnosis of invasive Aspergillus infections","volume":"6","author":"Alanio","year":"2017","journal-title":"F1000Res"},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"000699-19","DOI":"10.1128\/CMR.00069-19","article-title":"Antifungal susceptibility testing: current approaches","volume":"33","author":"Berkow","year":"2020","journal-title":"Clin Microbiol Rev."},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis."},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal pharmacokinetics and pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb Perspect Med."},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cid\/cir441","article-title":"Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition","volume":"53","author":"Nouer","year":"2011","journal-title":"Clin Infect Dis."},{"key":"R10-20250509","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/FTD.0000000000000507","article-title":"Exploring the use of C-reactive protein to estimate the pharmacodynamics of vancomycin","volume":"40","author":"Rawson","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R11-20250509","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20250509","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1128\/AAC.03023-15","article-title":"Pharmacodynamics of voriconazole in children: further steps along the path to true individualized therapy","volume":"60","author":"Huurneman","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R13-20250509","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/FTD.0000000000000799","article-title":"Population pharmacokinetics of voriconazole in patients with invasive aspergillosis: serum albumin level as a novel marker for clearance and dosage optimization","volume":"42","author":"Chantharit","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R14-20250509","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R15-20250509","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.00702-11","article-title":"Population pharmacokinetics of voriconazole in adults","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R16-20250509","doi-asserted-by":"crossref","first-page":"101435","DOI":"10.1016\/j.mycmed.2023.101435","article-title":"Clinical outcomes of aspergillosis among paediatric and adult inpatients: a multicentre study in a Brazilian metropolitan area","volume":"33","author":"Martins","year":"2023","journal-title":"J Mycol Med."},{"key":"R17-20250509","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1128\/AAC.05761-11","article-title":"Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults","volume":"56","author":"Friberg","year":"2012","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:10Z","timestamp":1746792010000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001268","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"assertion":[{"value":"2024-06-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}